Abstract: . . .  designation will drive development - Cumbersome infusion schedule may detract from broad clinical benefit • Phase II trial drugs - Enzastaurin (LY-317615; 317615.2HCI), Eli Lilly • Enzastaurin demonstrates clinical benefit in recurrent or progressive glioma • Overall enzastaurin had a favorable safety profile • Potential association of anti-cogulation therapy, enzastaurin and intratumoral bleeds • Phase III trials for enzastaurin planned • Significant uptake expected if Phase III trial results are positive - Erlotinib (Tarceva, Genentech/Roche/OSI) • Modest single agent activity in glioblastoma • Combining erlotinib with radiation appears to demonstrate acceptable toxicity • Race is on to identify biomarkers predictive of response • High EGFR expression and low levels of phosphorylated Akt may be suggestive of responder groups to erlotinib. • Further investigations need to be carried out to confirm these associations • Erlotinib will achieve significant uptake if efficacy shown OPINION LEADER TRANSCRIPTS • Contributing experts - European opinion leader 1 - European opinion leader 2 - US opinion leader 1 - US opinion leader 2 - US opinion leader 3 APPENDIX TABLES Table 1: Datamonitor estimates of glioblastoma incidence across the seven major markets, 2003-15 Table 2: Crude incidence rates of primary brain cancer in the seven major markets Table 3: Datamonitor estimates of the incidence of malignant brain cancer in the seven major markets, 2003-15 Table 4: Datamonitor estimates of . . .
. . .  __________________________________________________________________ ___________________ __________________ __________________________________________________________________ ___________________ __________________ __________________________________________________________________ ___________________ __________________ DMHC2102WEB * Please refer to our website www.datamonitor.com/healthcare for up-to-date prices. You can search for a product by Title or Product Code. From Europe: tel: +44 20 7675 7171 fax: +44 20 7675 7016 email: hcinfo@datamonitor.com From the US: tel: +1 212 652 5333 fax: +1 212 686 2626 email: usinfo@datamonitor.com From Asia Pacific: tel: +61 2 9006 1526 fax: +61 2 9006 1559 email: apinfo@datamonitor.com Contact us to find out more about our products and services  . . .
--3000,2,750,2448,25000